Literature DB >> 16430668

Silent myocardial ischaemia and haemoglobin concentration: a randomized controlled trial of transfusion strategy in lower limb arthroplasty.

M Grover1, S Talwalkar, A Casbard, H Boralessa, M Contreras, H Boralessa, S Brett, D R Goldhill, N Soni.   

Abstract

BACKGROUND AND OBJECTIVES: Red cell transfusion is commonly used in orthopaedic surgery. Evidence suggests that a restrictive transfusion strategy may be safe for most patients. However, concern has been raised over the risks of anaemia in those with ischaemic cardiac disease. Perioperative silent myocardial ischaemia (SMI) has a relatively high incidence in the elderly population undergoing elective surgery. This study used Holter monitoring to compare the effect of a restrictive and a liberal red cell transfusion strategy on the incidence of SMI in patients without signs or symptoms of ischaemic heart disease who were undergoing lower limb arthroplasty.
MATERIALS AND METHODS: We performed a multicentre, controlled trial in which 260 patients undergoing elective hip and knee replacement surgery were enrolled and randomized to transfusion triggers that were either restrictive (8 g/dl) or liberal (10 g/dl). Participants were monitored with continuous ambulatory electrocardiogram (ECG) (Holter monitoring), preoperatively for 12 h and postoperatively for 72 h. The tapes were analysed for new ischaemia by technicians blinded to treatment. The total ischaemia time in minutes was divided by the recording time in hours and an ischaemic load in min/h was calculated. Haemoglobin levels were measured preoperatively, postoperatively in the recovery room, and on days one, three and five after surgery.
RESULTS: The mean postoperative haemoglobin concentration was 9.87 g/dl in the restrictive group and 11.09 g/dl in the liberal group. In the restrictive group, 34% were transfused a total of 89 red cell units, and in the liberal group 43% were given a total of 119 red cell units. A postoperative episode of silent ischaemia was experienced by 21/109 (19%) patients in the restrictive group and by 26/109 (24%) patients in the liberal group [mean difference -4.6%; 95% confidence interval (CI): -15.5% to 6%, P = 0.41). There was no significant difference (P = 0.53) between the overall ischaemic load in the restrictive group (median 0 min/h, range 0-4.18) and the liberal group (median 0 min/h, range 0-19.48). In those patients who did experience postoperative SMI, the mean ischaemic load was 0.48 min/h in the restrictive group and 1.51 min/h in the liberal group (ratio 0.32, 95% CI: 0.14-0.76, P = 0.011). The median postoperative length of hospital stay in the restrictive group was 7.3 days [range 5-11; interquartile range (IQR) 6-8] compared with 7.5 days (range 5-13; IQR 7-8) in the liberal group. The numbers were not large enough to conclude equivalence.
CONCLUSIONS: In patients without preoperative evidence of myocardial ischaemia undergoing elective hip and knee replacement surgery, a restrictive transfusion strategy seems unlikely to be associated with an increased incidence of SMI. A proportion of these patients experience moderate SMI, regardless of the transfusion trigger. Use of a restrictive transfusion strategy did not increase length of hospital stay, and use of this strategy would lead to a significant reduction in red cell transfusion in orthopaedic surgery. Our data did not indicate any potential for harm in employing such a strategy in patients with no prior evidence of cardiac ischaemia who were undergoing elective orthopaedic surgery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16430668     DOI: 10.1111/j.1423-0410.2006.00730.x

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  34 in total

Review 1.  On the role of iron therapy for reducing allogeneic blood transfusion in orthopaedic surgery.

Authors:  Manuel Muñoz; José Antonio García-Erce; Jorge Cuenca; Elvira Bisbe; Enrique Naveira
Journal:  Blood Transfus       Date:  2011-11-30       Impact factor: 3.443

Review 2.  [Patient Blood Management : three pillar strategy to improve outcome through avoidance of allogeneic blood products].

Authors:  H Gombotz; A Hofmann
Journal:  Anaesthesist       Date:  2013-07       Impact factor: 1.041

3.  Spanish Consensus Statement on alternatives to allogeneic blood transfusion: the 2013 update of the "Seville Document".

Authors:  Santiago R Leal-Noval; Manuel Muñoz; Marisol Asuero; Enric Contreras; José A García-Erce; Juan V Llau; Victoria Moral; José A Páramo; Manuel Quintana
Journal:  Blood Transfus       Date:  2013-06-17       Impact factor: 3.443

4.  Favourable results of a new intraoperative and postoperative filtered autologous blood re-transfusion system in total hip arthroplasty: a randomised controlled trial.

Authors:  Wieger G Horstmann; Martzen J Swierstra; David Ohanis; Rob Rolink; Boudewijn J Kollen; Cees C P M Verheyen
Journal:  Int Orthop       Date:  2014-01       Impact factor: 3.075

Review 5.  [Erythrocyte transfusion: update of the guidelines "therapy with blood components and plasma derivatives"].

Authors:  M Welte
Journal:  Anaesthesist       Date:  2009-11       Impact factor: 1.041

6.  1 RBC Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

7.  Renal and Gastrointestinal Considerations in Joint Replacement Surgery.

Authors:  Benjamin Voss; Alexander Kurdi; Alexander Skopec; Jasmine Saleh; Mouhanad M El-Othmani; Joseph M Lane; William M Mihalko; Khaled J Saleh
Journal:  J Nat Sci       Date:  2015-02-01

8.  A new perspective on best transfusion practices.

Authors:  Aryeh Shander; Irwin Gross; Steven Hill; Mazyar Javidroozi; Sharon Sledge
Journal:  Blood Transfus       Date:  2013-01-22       Impact factor: 3.443

9.  Restrictive transfusion triggers in major orthopaedic surgery: effective and safe?

Authors:  Manuel Muñoz; Santiago Ramón Leal-Noval
Journal:  Blood Transfus       Date:  2013-02-06       Impact factor: 3.443

Review 10.  Blood transfusion for the treatment of acute anaemia in inflammatory bowel disease and other digestive diseases.

Authors:  José Antonio García-Erce; Fernando Gomollón; Manuel Muñoz
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.